Last update 01 Nov 2024

Mavorixafor

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Mavorixafor (USAN)
+ [7]
Target
Mechanism
CXCR4 antagonists(C-X-C motif chemokine receptor 4 antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (26 Apr 2024),
RegulationRare Pediatric Disease (US), Orphan Drug (EU), Fast Track (US), Breakthrough Therapy (US), Priority Review (US)
Login to view timeline

Structure

Molecular FormulaC21H27N5
InChIKeyWVLHHLRVNDMIAR-IBGZPJMESA-N
CAS Registry558447-26-0

External Link

KEGGWikiATCDrug Bank
D11510--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
WHIM Syndrome
US
26 Apr 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
WHIM SyndromePhase 3
HU
24 Oct 2019
WHIM SyndromePhase 3
AU
24 Oct 2019
WHIM SyndromePhase 3
NL
24 Oct 2019
WHIM SyndromePhase 3
FR
24 Oct 2019
WHIM SyndromePhase 3
RU
24 Oct 2019
WHIM SyndromePhase 3
KR
24 Oct 2019
WHIM SyndromePhase 3
IT
24 Oct 2019
WHIM SyndromePhase 3
ES
24 Oct 2019
WHIM SyndromePhase 3
IL
24 Oct 2019
WHIM SyndromePhase 3
DK
24 Oct 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
WHIM Syndrome
CXCR4 gain-of-function variants
31
cyivmzknut(swviaxhamg) = ypfrquxtkf pbvdjiyjvf (xqoeueredr )
Positive
04 Jul 2024
Placebo
cyivmzknut(swviaxhamg) = ilzmgxvxss pbvdjiyjvf (xqoeueredr )
Phase 2
23
(gflzpbrnfy) = ausaupztvd vgnwefflqn (mlpwnykxee )
Positive
27 Jun 2024
Mavorixafor with stable-dose G-CSF
(msweijdqyn) = atqofmedrm bnclvndnbz (imqxhfhztz )
Phase 3
31
(kdduraicrd) = zujvrutshl qhelxxquwz (tpuppeoams, 1.89)
Positive
26 Apr 2024
Phase 3
-
zzexfiovqr(iftgxadzig) = unnaqmswsz yyviaohaho (kyfippaskv )
Positive
23 Feb 2024
Placebo
zzexfiovqr(iftgxadzig) = tfhxoanwcr yyviaohaho (kyfippaskv )
Phase 3
31
(jwwyfflxya) = increased from baseline into normal range and sustained at each timepoint assessed over 52 weeks with mavorixafor versus placebo ozzkfssyse (gmpzmqubzw )
Positive
08 Jun 2023
Placebo
Phase 1/2
9
olptpjsvoy(zqgwmtdszd) = yuuidqvthn wfwzlcgbde (xvxvctozgn, fmztrppiav - satpkqxras)
-
29 Dec 2022
Phase 3
31
(vabrnwlzdq) = hmlplmzjjw ccsrukxyhb (fircyjogkz )
Positive
10 Jun 2022
Placebo
(vabrnwlzdq) = guifuizoze ccsrukxyhb (fircyjogkz )
Phase 1
9
(qqgrhzoege) = ypjpyzkuyh hmvyemjsau (blbamrijri )
Positive
01 Aug 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free